

Maria Pia amato

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8772511/publications.pdf>

Version: 2024-02-01

285
papers

19,632
citations

9264

74
h-index

15266

126
g-index

294
all docs

294
docs citations

294
times ranked

10730
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Impact of COVID-19 on multiple sclerosis care and management: Results from the European Committee for Treatment and Research in Multiple Sclerosis survey. <i>Multiple Sclerosis Journal</i> , 2022, 28, 132-138. | 3.0 | 31 |
| 2 | PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study. <i>Journal of Neurology</i> , 2022, 269, 933-944. | 3.6 | 10 |
| 3 | Pregnancy in multiple sclerosis women with relapses in the year before conception increases the risk of long-term disability worsening. <i>Multiple Sclerosis Journal</i> , 2022, 28, 472-479. | 3.0 | 13 |
| 4 | Mild gray matter atrophy in patients with long-standing multiple sclerosis and favorable clinical course. <i>Multiple Sclerosis Journal</i> , 2022, 28, 154-159. | 3.0 | 3 |
| 5 | Cardiorespiratory fitness and free-living physical activity are not associated with cognition in persons with progressive multiple sclerosis: Baseline analyses from the CogEx study. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1091-1100. | 3.0 | 10 |
| 6 | Performance of the 2017 and 2010 Revised McDonald Criteria in Predicting MS Diagnosis After a Clinically Isolated Syndrome. <i>Neurology</i> , 2022, 98, . | 1.1 | 31 |
| 7 | Risk of Getting COVID-19 in People With Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, . | 6.0 | 31 |
| 8 | Comparing natural history of early and late onset pediatric multiple sclerosis. <i>Annals of Neurology</i> , 2022, , . | 5.3 | 6 |
| 9 | The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1424-1456. | 3.0 | 16 |
| 10 | Secondary Prevention in Radiologically Isolated Syndromes and Prodromal Stages of Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2022, 13, 787160. | 2.4 | 9 |
| 11 | Natalizumab treatment and pregnancy in multiple sclerosis: A reappraisal of maternal and infant outcomes after 6 years. <i>Multiple Sclerosis Journal</i> , 2022, 28, 2137-2141. | 3.0 | 3 |
| 12 | The agenda of the global patient reported outcomes for multiple sclerosis (PROMS) initiative: Progresses and open questions. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 61, 103757. | 2.0 | 10 |
| 13 | Long-term Cognitive Outcomes and Socioprofessional Attainment in People With Multiple Sclerosis With Childhood Onset. <i>Neurology</i> , 2022, 98, e1626-e1636. | 1.1 | 7 |
| 14 | The relationship between processing speed and verbal and non-verbal new learning and memory in progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2022, , 135245852210881. | 3.0 | 5 |
| 15 | Early use of high-efficacy disease-modifying therapies makes the difference in people with multiple sclerosis: an expert opinion. <i>Journal of Neurology</i> , 2022, 269, 5382-5394. | 3.6 | 32 |
| 16 | The introduction of new medications in pediatric multiple sclerosis: Open issues and challenges. <i>Multiple Sclerosis Journal</i> , 2021, 27, 479-482. | 3.0 | 7 |
| 17 | Gray matter atrophy cannot be fully explained by white matter damage in patients with MS. <i>Multiple Sclerosis Journal</i> , 2021, 27, 39-51. | 3.0 | 21 |
| 18 | Understanding the pathophysiology of cognitive changes in MS: A step forward. <i>Multiple Sclerosis Journal</i> , 2021, 27, 4-5. | 3.0 | 1 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors. <i>Multiple Sclerosis Journal</i> , 2021, 27, 430-438. | 3.0 | 19 |
| 20 | Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study. <i>European Journal of Neurology</i> , 2021, 28, 1299-1307. | 3.3 | 12 |
| 21 | The Contribution of Illness Beliefs, Coping Strategies, and Social Support to Perceived Physical Health and Fatigue in Multiple Sclerosis. <i>Journal of Clinical Psychology in Medical Settings</i> , 2021, 28, 149-160. | 1.4 | 17 |
| 22 | Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies. <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642110195. | 3.5 | 48 |
| 23 | Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register. <i>Neurotherapeutics</i> , 2021, 18, 905-919. | 4.4 | 9 |
| 24 | Early Predictors of 9â€¢Year Disability in Pediatric Multiple Sclerosis. <i>Annals of Neurology</i> , 2021, 89, 1011-1022. | 5.3 | 13 |
| 25 | Cognitive Issues in Pediatric Multiple Sclerosis. <i>Brain Sciences</i> , 2021, 11, 442. | 2.3 | 18 |
| 26 | The Brain-Derived Neurotrophic Factor Val66Met Polymorphism Can Protect Against Cognitive Impairment in Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2021, 12, 645220. | 2.4 | 13 |
| 27 | Natalizumab, Fingolimod, and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis. <i>Neurology</i> , 2021, 96, . | 1.1 | 41 |
| 28 | Identifying the Distinct Cognitive Phenotypes in Multiple Sclerosis. <i>JAMA Neurology</i> , 2021, 78, 414. | 9.0 | 86 |
| 29 | Effects of High- and Low-Efficacy Therapy in Secondary Progressive Multiple Sclerosis. <i>Neurology</i> , 2021, 97, e869-e880. | 1.1 | 15 |
| 30 | Current international trends in the treatment of multiple sclerosis in childrenâ€¢Impact of the COVID-19 pandemic. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 56, 103277. | 2.0 | 5 |
| 31 | Safety and Efficacy of Eculizumab Therapy in Multiple Sclerosis: A Case Series. <i>Brain Sciences</i> , 2021, 11, 1341. | 2.3 | 7 |
| 32 | Cerebrospinal Fluid IgM and Oligoclonal IgG Bands in Multiple Sclerosis: A Meta-Analysis of Prevalence and Prognosis. <i>Brain Sciences</i> , 2021, 11, 1444. | 2.3 | 5 |
| 33 | Etiological research in pediatric multiple sclerosis: A tool to assess environmental exposures (PEDiatric Italian Genetic and enviRonment ExposurE Questionnaire). <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021, 7, 205521732110590. | 1.0 | 1 |
| 34 | Illness perceptions and psychological adjustment among persons with multiple sclerosis: the mediating role of coping strategies and social support. <i>Disability and Rehabilitation</i> , 2020, 42, 3780-3792. | 1.8 | 17 |
| 35 | Tracking cognitive impairment in multiple sclerosis using the Brain on Track test: a validation study. <i>Neurological Sciences</i> , 2020, 41, 183-191. | 1.9 | 5 |
| 36 | The caring experience in multiple sclerosis: Caregiving tasks, coping strategies and psychological wellâ€¢being. <i>Health and Social Care in the Community</i> , 2020, 28, 236-246. | 1.6 | 17 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 37 | Sex effects across the lifespan in women with multiple sclerosis. <i>Therapeutic Advances in Neurological Disorders</i> , 2020, 13, 175628642093616. | 3.5 | 58 |
| 38 | Delay from treatment start to full effect of immunotherapies for multiple sclerosis. <i>Brain</i> , 2020, 143, 2742-2756. | 7.6 | 24 |
| 39 | Cognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues. <i>Lancet Neurology</i> , The, 2020, 19, 860-871. | 10.2 | 302 |
| 40 | Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis. <i>Brain</i> , 2020, 143, 3013-3024. | 7.6 | 53 |
| 41 | Effects of 2-year treatment with dimethyl fumarate on cognition and functional impairment in patients with relapsing remitting multiple sclerosis. <i>Neurological Sciences</i> , 2020, 41, 3185-3193. | 1.9 | 15 |
| 42 | Aggressive multiple sclerosis (2): Treatment. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1045-1063. | 3.0 | 21 |
| 43 | Aggressive multiple sclerosis (1): Towards a definition of the phenotype. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1031-1044. | 3.0 | 39 |
| 44 | Radiologically Isolated Syndrome: $10\text{â€}^{\text{Year}}$ Risk Estimate of a Clinical Event. <i>Annals of Neurology</i> , 2020, 88, 407-417. | 5.3 | 95 |
| 45 | Disease-modifying therapy aids cognition in multiple sclerosis. <i>Nature Reviews Neurology</i> , 2020, 16, 525-526. | 10.1 | 7 |
| 46 | Study protocol: improving cognition in people with progressive multiple sclerosis: a multi-arm, randomized, blinded, sham-controlled trial of cognitive rehabilitation and aerobic exercise (COGEx). <i>BMC Neurology</i> , 2020, 20, 204. | 1.8 | 30 |
| 47 | A method to compare prospective and historical cohorts to evaluate drug effects. Application to the analysis of early treatment effectiveness of intramuscular interferon- β 1a in multiple sclerosis patients. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 40, 101952. | 2.0 | 0 |
| 48 | Cognitive impairment in multiple sclerosis: An exploratory analysis of environmental and lifestyle risk factors. <i>PLoS ONE</i> , 2019, 14, e0222929. | 2.5 | 32 |
| 49 | Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register. <i>Journal of Neurology</i> , 2019, 266, 3098-3107. | 3.6 | 1 |
| 50 | Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. <i>Lancet Neurology</i> , The, 2019, 18, 185-197. | 10.2 | 110 |
| 51 | Aging with multiple sclerosis: prevalence and profile of cognitive impairment. <i>Neurological Sciences</i> , 2019, 40, 1651-1657. | 1.9 | 39 |
| 52 | Identifying risk factors for cognitive issues in multiple sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 333-347. | 2.8 | 27 |
| 53 | Breastfeeding and post-partum relapses in multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1211-1216. | 3.0 | 21 |
| 54 | The Italian multiple sclerosis register. <i>Neurological Sciences</i> , 2019, 40, 155-165. | 1.9 | 59 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 55 | Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study. <i>Multiple Sclerosis Journal</i> , 2019, 25, 399-407. | 3.0 | 38 |
| 56 | Radiologically isolated syndrome or subclinical multiple sclerosis: MAGNIMS consensus recommendations. <i>Multiple Sclerosis Journal</i> , 2018, 24, 214-221. | 3.0 | 77 |
| 57 | Pregnancy decision-making in women with multiple sclerosis treated with natalizumab. <i>Neurology</i> , 2018, 90, e823-e831. | 1.1 | 102 |
| 58 | Progress in multiple sclerosis – from diagnosis to therapy. <i>Nature Reviews Neurology</i> , 2018, 14, 72-74. | 10.1 | 8 |
| 59 | “Brain reserve” and “cognitive reserve” should always be taken into account when studying neurodegeneration” Commentary. <i>Multiple Sclerosis Journal</i> , 2018, 24, 577-578. | 3.0 | 1 |
| 60 | Pregnancy decision-making in women with multiple sclerosis treated with natalizumab. <i>Neurology</i> , 2018, 90, e832-e839. | 1.1 | 74 |
| 61 | <scp>ECTRIMS</scp>/<scp>EAN</scp> guideline on the pharmacological treatment of people with multiple sclerosis. <i>European Journal of Neurology</i> , 2018, 25, 215-237. | 3.3 | 147 |
| 62 | ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 96-120. | 3.0 | 458 |
| 63 | Environmental modifiable risk factors for multiple sclerosis: Report from the 2016 ECTRIMS focused workshop. <i>Multiple Sclerosis Journal</i> , 2018, 24, 590-603. | 3.0 | 101 |
| 64 | Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 642-652. | 3.0 | 37 |
| 65 | Patients with paediatric-onset multiple sclerosis are at higher risk of cognitive impairment in adulthood: An Italian collaborative study. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1234-1242. | 3.0 | 33 |
| 66 | Author response: Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks. <i>Neurology</i> , 2018, 91, 851-851. | 1.1 | 4 |
| 67 | A case of Takotsubo syndrome during a multiple sclerosis brainstem relapse. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 24, 1-2. | 2.0 | 10 |
| 68 | Cognitive assessment in multiple sclerosis – an Italian consensus. <i>Neurological Sciences</i> , 2018, 39, 1317-1324. | 1.9 | 37 |
| 69 | A decline in cognitive function should lead to a change in disease-modifying therapy” Commentary. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1685-1686. | 3.0 | 4 |
| 70 | The dilemma of benign multiple sclerosis: Can we predict the risk of losing the “benign status”? A 12-year follow-up study. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 26, 71-73. | 2.0 | 6 |
| 71 | Contribution of different relapse phenotypes to disability in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017, 23, 266-276. | 3.0 | 30 |
| 72 | Effect of organizational features on patient satisfaction with care in Italian multiple sclerosis centres. <i>European Journal of Neurology</i> , 2017, 24, 631-637. | 3.3 | 15 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 196-203. | 1.9 | 49 |
| 74 | The diagnostic dilemma of multiple sclerosis presenting with isolated cognitive and behavioral disorders. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1561-1563. | 3.0 | 1 |
| 75 | Prognostic indicators in pediatric clinically isolated syndrome. <i>Annals of Neurology</i> , 2017, 81, 729-739. | 5.3 | 34 |
| 76 | Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsingâ€“remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study). <i>Journal of Neurology</i> , 2017, 264, 2436-2449. | 3.6 | 44 |
| 77 | Clinical outcome measures for progressive MS trials. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1627-1635. | 3.0 | 32 |
| 78 | MRI substrates of sustained attention system and cognitive impairment in pediatric MS patients. <i>Neurology</i> , 2017, 89, 1265-1273. | 1.1 | 13 |
| 79 | Maturational Trajectory of Processing Speed Performance in Pediatric Multiple Sclerosis. <i>Developmental Neuropsychology</i> , 2017, 42, 299-308. | 1.4 | 4 |
| 80 | Management of pregnancy-related issues in multiple sclerosis patients: the need for an interdisciplinary approach. <i>Neurological Sciences</i> , 2017, 38, 1849-1858. | 1.9 | 30 |
| 81 | The still under-investigated role of cognitive deficits in PML diagnosis. <i>Multiple Sclerosis and Demyelinating Disorders</i> , 2017, 2, . | 1.1 | 4 |
| 82 | Disease modifying treatments and symptomatic drugs for cognitive impairment in multiple sclerosis: where do we stand?. <i>Multiple Sclerosis and Demyelinating Disorders</i> , 2017, 2, . | 1.1 | 7 |
| 83 | Age and disability drive cognitive impairment in multiple sclerosis across disease subtypes. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1258-1267. | 3.0 | 209 |
| 84 | Towards personalized therapy for multiple sclerosis: prediction of individual treatment response. <i>Brain</i> , 2017, 140, 2426-2443. | 7.6 | 94 |
| 85 | Beyond Disease: Happiness, Goals, and Meanings among Persons with Multiple Sclerosis and Their Caregivers. <i>Frontiers in Psychology</i> , 2017, 8, 2216. | 2.1 | 30 |
| 86 | Pronounced Structural and Functional Damage in Early Adult Pediatric-Onset Multiple Sclerosis with No or Minimal Clinical Disability. <i>Frontiers in Neurology</i> , 2017, 8, 608. | 2.4 | 19 |
| 87 | Thrombotic microangiopathy induced by interferon beta in patients with multiple sclerosis: three cases treated with eculizumab. <i>CKJ: Clinical Kidney Journal</i> , 2017, 10, 625-631. | 2.9 | 26 |
| 88 | Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, jnnp-2014-309903. | 1.9 | 162 |
| 89 | Defining secondary progressive multiple sclerosis. <i>Brain</i> , 2016, 139, 2395-2405. | 7.6 | 281 |
| 90 | Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1343-1349. | 1.9 | 63 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 944-951. | 1.9 | 88 |
| 92 | History of multiple sclerosis in 2 successive pregnancies. <i>Neurology</i> , 2016, 87, 1360-1367. | 1.1 | 16 |
| 93 | Pediatric multiple sclerosis. <i>Neurology</i> , 2016, 87, S97-S102. | 1.1 | 67 |
| 94 | International Pediatric MS Study Group Global Members Symposium report. <i>Neurology</i> , 2016, 87, S110-6. | 1.1 | 19 |
| 95 | Pediatric multiple sclerosis. <i>Neurology</i> , 2016, 87, S82-7. | 1.1 | 78 |
| 96 | Pediatric multiple sclerosis. <i>Neurology</i> , 2016, 87, S74-81. | 1.1 | 107 |
| 97 | The heritage of glatiramer acetate and its use in multiple sclerosis. <i>Multiple Sclerosis and Demyelinating Disorders</i> , 2016, 1, . | 1.1 | 14 |
| 98 | Primary <sc>P</sc>rogressive <sc>M</sc>ultiple <sc>S</sc>clerosis <sc>E</sc>volving <sc>F</sc>rom <sc>R</sc>adiologically <sc>I</sc>solated <sc>S</sc>yndrome. <i>Annals of Neurology</i> , 2016, 79, 288-294. | 5.3 | 130 |
| 99 | No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon \hat{I}^2 1b therapy in relapsingâremitting multiple sclerosis (the ARIANNA study). <i>Multiple Sclerosis Journal</i> , 2016, 22, 1163-1173. | 3.0 | 24 |
| 100 | The cognitive reserve theory in the setting of pediatric-onset multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1741-1749. | 3.0 | 32 |
| 101 | A 10-year follow-up of the European multicenter trial of interferon \hat{I}^2 -1b in secondary-progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 533-543. | 3.0 | 24 |
| 102 | Illness Perception and Well-Being Among Persons with Multiple Sclerosis and Their Caregivers. <i>Journal of Clinical Psychology in Medical Settings</i> , 2016, 23, 33-52. | 1.4 | 39 |
| 103 | Regional hippocampal involvement and cognitive impairment in pediatric multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 628-640. | 3.0 | 28 |
| 104 | Immunomodulatory therapies delay disease progression in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1732-1740. | 3.0 | 48 |
| 105 | The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 520-532. | 3.0 | 34 |
| 106 | Abnormal cerebellar functional MRI connectivity in patients with paediatric multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 292-301. | 3.0 | 16 |
| 107 | The Use of Immunosuppressant Therapy for Multiple Sclerosis in Italy: A Multicenter Retroprospective Study. <i>PLoS ONE</i> , 2016, 11, e0157721. | 2.5 | 5 |
| 108 | A comparison of the brief international cognitive assessment for multiple sclerosis and the brief repeatable battery in multiple sclerosis patients. <i>BMC Neurology</i> , 2015, 15, 204. | 1.8 | 31 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 109 | Multiple sclerosis in Latin America: A different disease course severity? A collaborative study from the MSBase Registry. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2015, 1, 205521731560019. | 1.0 | 5 |
| 110 | A steroid-induced bilateral avascular necrosis of the femoral head in an underage patient affected by multiple sclerosis. <i>Clinical Cases in Mineral and Bone Metabolism</i> , 2015, 12, 257-9. | 1.0 | 9 |
| 111 | Autologous hematopoietic stem cell transplantation in multiple sclerosis. <i>Neurology</i> , 2015, 84, 981-988. | 1.1 | 201 |
| 112 | Clinical and imaging assessment of cognitive dysfunction in multiple sclerosis. <i>Lancet Neurology</i> , The, 2015, 14, 302-317. | 10.2 | 437 |
| 113 | Cognitive impairment in paediatric multiple sclerosis patients is not related to cortical lesions. <i>Multiple Sclerosis Journal</i> , 2015, 21, 956-959. | 3.0 | 21 |
| 114 | Dysregulation of sphingosine 1 phosphate receptor-1 (S1P1) signaling and regulatory lymphocyte-dependent immunosuppression in a model of post-fingolimod MS rebound. <i>Brain, Behavior, and Immunity</i> , 2015, 50, 78-86. | 4.1 | 48 |
| 115 | Predictors of disability worsening in clinically isolated syndrome. <i>Annals of Clinical and Translational Neurology</i> , 2015, 2, 479-491. | 3.7 | 43 |
| 116 | Fertility, Pregnancy and Childbirth in Patients with Multiple Sclerosis: Impact of Disease-Modifying Drugs. <i>CNS Drugs</i> , 2015, 29, 207-220. | 5.9 | 75 |
| 117 | Appraisal of Brain Connectivity in Radiologically Isolated Syndrome by Modeling Imaging Measures. <i>Journal of Neuroscience</i> , 2015, 35, 550-558. | 3.6 | 42 |
| 118 | Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis. <i>JAMA Neurology</i> , 2015, 72, 405. | 9.0 | 100 |
| 119 | Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis. <i>Brain</i> , 2015, 138, 3275-3286. | 7.6 | 76 |
| 120 | Long-term assessment of no evidence of disease activity in relapsing-remitting MS. <i>Neurology</i> , 2015, 85, 1722-1723. | 1.1 | 26 |
| 121 | Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1159-1171. | 3.0 | 36 |
| 122 | Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS. <i>PLoS ONE</i> , 2015, 10, e0122686. | 2.5 | 122 |
| 123 | Less Frequent and Less Severe Flu-Like Syndrome in Interferon Beta-1a Treated Multiple Sclerosis Patients with at Least One Allele Bearing the G>C Polymorphism at Position -174 of the IL-6 Promoter Gene. <i>PLoS ONE</i> , 2015, 10, e0135441. | 2.5 | 3 |
| 124 | Assessing executive function with the D-KEFS sorting test: normative data for a sample of the Italian adult population. <i>Neurological Sciences</i> , 2014, 35, 1895-1902. | 1.9 | 23 |
| 125 | Intranetwork and internetwork functional connectivity abnormalities in pediatric multiple sclerosis. <i>Human Brain Mapping</i> , 2014, 35, 4180-4192. | 3.6 | 40 |
| 126 | Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 845-850. | 1.9 | 66 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 127 | The brief international cognitive assessment for multiple sclerosis (BICAMS): normative values with gender, age and education corrections in the Italian population. <i>BMC Neurology</i> , 2014, 14, 171. | 1.8 | 99 |
| 128 | Computer-assisted rehabilitation of attention in patients with multiple sclerosis: results of a randomized, double-blind trial. <i>Multiple Sclerosis Journal</i> , 2014, 20, 91-98. | 3.0 | 103 |
| 129 | Risk of relapse phenotype recurrence in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1511-1522. | 3.0 | 73 |
| 130 | Posterior brain damage and cognitive impairment in pediatric multiple sclerosis. <i>Neurology</i> , 2014, 82, 1314-1321. | 1.1 | 56 |
| 131 | The Rao's Brief Repeatable Battery version B: normative values with age, education and gender corrections in an Italian population. <i>Neurological Sciences</i> , 2014, 35, 79-82. | 1.9 | 31 |
| 132 | Guidelines on the clinical use for the detection of neutralizing antibodies (NABs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group. <i>Neurological Sciences</i> , 2014, 35, 307-316. | 1.9 | 30 |
| 133 | Predictors and dynamics of postpartum relapses in women with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014, 20, 739-746. | 3.0 | 148 |
| 134 | Neuropsychological features in childhood and juvenile multiple sclerosis. <i>Neurology</i> , 2014, 83, 1432-1438. | 1.1 | 227 |
| 135 | Seasonal variation of relapse rate in multiple sclerosis is latitude dependent. <i>Annals of Neurology</i> , 2014, 76, 880-890. | 5.3 | 67 |
| 136 | Relevance of hypointense brain MRI lesions for long-term worsening of clinical disability in relapsing multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014, 20, 214-219. | 3.0 | 51 |
| 137 | Anxiety state affects information processing speed in patients with multiple sclerosis. <i>Neurological Sciences</i> , 2014, 35, 559-563. | 1.9 | 51 |
| 138 | The coexistence of well- and ill-being in persons with multiple sclerosis, their caregivers and health professionals. <i>Journal of the Neurological Sciences</i> , 2014, 337, 67-73. | 0.6 | 37 |
| 139 | Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study. <i>BMC Neurology</i> , 2014, 14, 114. | 1.8 | 27 |
| 140 | Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial. <i>BMC Neurology</i> , 2014, 14, 65. | 1.8 | 47 |
| 141 | Emotional and neutral verbal memory impairment in Multiple Sclerosis. <i>Journal of the Neurological Sciences</i> , 2014, 341, 28-31. | 0.6 | 11 |
| 142 | Radiologically Isolated Syndrome: 5-Year Risk for an Initial Clinical Event. <i>PLoS ONE</i> , 2014, 9, e90509. | 2.5 | 254 |
| 143 | MxA mRNA Quantification and Disability Progression in Interferon Beta-Treated Multiple Sclerosis Patients. <i>PLoS ONE</i> , 2014, 9, e94794. | 2.5 | 14 |
| 144 | Treatment of cognitive impairment in multiple sclerosis: position paper. <i>Journal of Neurology</i> , 2013, 260, 1452-1468. | 3.6 | 189 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 145 | Rebound after Fingolimod suspension in a pediatric-onset multiple sclerosis patient. <i>Journal of Neurology</i> , 2013, 260, 1675-1677. | 3.6 | 23 |
| 146 | Increased CD8+ T cell responses to apoptotic T cell-associated antigens in multiple sclerosis. <i>Journal of Neuroinflammation</i> , 2013, 10, 94. | 7.2 | 22 |
| 147 | Current recommendations for multiple sclerosis treatment in pregnancy and puerperium. <i>Expert Review of Clinical Immunology</i> , 2013, 9, 683-692. | 3.0 | 17 |
| 148 | International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1261-1267. | 3.0 | 883 |
| 149 | Sex as a determinant of relapse incidence and progressive course of multiple sclerosis. <i>Brain</i> , 2013, 136, 3609-3617. | 7.6 | 140 |
| 150 | Immunohistochemistry analysis of bone marrow biopsies in multiple sclerosis patients undergoing autologous haematopoietic stem cells transplantation. <i>Clinical Neurology and Neurosurgery</i> , 2013, 115, 1044-1048. | 1.4 | 4 |
| 151 | Fluctuations of MS births and UV-light exposure. <i>Acta Neurologica Scandinavica</i> , 2013, 127, 301-308. | 2.1 | 10 |
| 152 | Prevalence of patient-reported dysphagia in multiple sclerosis patients: An Italian multicenter study (using the DYMUS questionnaire). <i>Journal of the Neurological Sciences</i> , 2013, 331, 94-97. | 0.6 | 53 |
| 153 | Persistence on Therapy and Propensity Matched Outcome Comparison of Two Subcutaneous Interferon Beta 1a Dosages for Multiple Sclerosis. <i>PLoS ONE</i> , 2013, 8, e63480. | 2.5 | 26 |
| 154 | Endovascular treatment of CCSVI in patients with multiple sclerosis: clinical outcome of 462 cases. <i>Neurological Sciences</i> , 2013, 34, 1633-1637. | 1.9 | 20 |
| 155 | Brain metabolic changes suggestive of axonal damage in radiologically isolated syndrome. <i>Neurology</i> , 2013, 80, 2090-2094. | 1.1 | 63 |
| 156 | Adverse events after endovascular treatment of chronic cerebro-spinal venous insufficiency (CCSVI) in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 961-963. | 3.0 | 17 |
| 157 | Cognitive reserve and cortical atrophy in multiple sclerosis. <i>Neurology</i> , 2013, 80, 1728-1733. | 1.1 | 113 |
| 158 | Natalizumab may reduce cognitive changes and brain atrophy rate in relapsing–remitting multiple sclerosis: a prospective, non–randomized pilot study. <i>European Journal of Neurology</i> , 2013, 20, 986-990. | 3.3 | 46 |
| 159 | Clinical case reviews in multiple sclerosis spasticity: experiences from around Europe. <i>Expert Review of Neurotherapeutics</i> , 2013, 13, 61-66. | 2.8 | 4 |
| 160 | Subcutaneous Interferon β -1a May Protect against Cognitive Impairment in Patients with Relapsing–Remitting Multiple Sclerosis: 5-Year Follow-up of the COGIMUS Study. <i>PLoS ONE</i> , 2013, 8, e74111. | 2.5 | 53 |
| 161 | A prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: a position paper. <i>Multiple Sclerosis Journal</i> , 2012, 18, 825-834. | 3.0 | 89 |
| 162 | No association between chronic cerebrospinal venous insufficiency and pediatric-onset multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012, 18, 1791-1796. | 3.0 | 19 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 163 | Fatigue and its relationships with cognitive functioning and depression in paediatric multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012, 18, 329-334. | 3.0 | 77 |
| 164 | Association of MRI metrics and cognitive impairment in radiologically isolated syndromes. <i>Neurology</i> , 2012, 78, 309-314. | 1.1 | 169 |
| 165 | Cognitive and Psychosocial Issues in Pediatric Multiple Sclerosis: Where We Are and Where We Need To Go. <i>Neuropediatrics</i> , 2012, 43, 174-175. | 0.6 | 4 |
| 166 | Recommendations for a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS). <i>Multiple Sclerosis Journal</i> , 2012, 18, 891-898. | 3.0 | 654 |
| 167 | Truly benign multiple sclerosis is rare: let's stop fooling ourselves-Yes. <i>Multiple Sclerosis Journal</i> , 2012, 18, 13-14. | 3.0 | 20 |
| 168 | Withdrawal of fingolimod treatment for relapsing-remitting multiple sclerosis: report of six cases. <i>Multiple Sclerosis Journal</i> , 2012, 18, 1636-1639. | 3.0 | 50 |
| 169 | Longitudinal changes in social functioning in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon β -1a: results from the COGIMUS (COGNitive) Tj ETQq1 1 0.784314 rgBTg/Overlook | 1.0 | 14 |
| 170 | Management options in multiple sclerosis-associated fatigue. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 207-216. | 1.8 | 46 |
| 171 | Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study. <i>BMC Neurology</i> , 2012, 12, 124. | 1.8 | 82 |
| 172 | Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study. <i>BMC Neurology</i> , 2012, 12, 165. | 1.8 | 78 |
| 173 | Brief International Cognitive Assessment for MS (BICAMS): international standards for validation. <i>BMC Neurology</i> , 2012, 12, 55. | 1.8 | 275 |
| 174 | Consensus statement: evaluation of new and existing therapeutics for pediatric multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012, 18, 116-127. | 3.0 | 186 |
| 175 | Impact of Natalizumab on Cognitive Performances and Fatigue in Relapsing Multiple Sclerosis: A Prospective, Open-Label, Two Years Observational Study. <i>PLoS ONE</i> , 2012, 7, e35843. | 2.5 | 82 |
| 176 | Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience. <i>Multiple Sclerosis Journal</i> , 2012, 18, 835-842. | 3.0 | 115 |
| 177 | Relevance of Brain Lesion Location to Cognition in Relapsing Multiple Sclerosis. <i>PLoS ONE</i> , 2012, 7, e44826. | 2.5 | 78 |
| 178 | Geographical Variations in Sex Ratio Trends over Time in Multiple Sclerosis. <i>PLoS ONE</i> , 2012, 7, e48078. | 2.5 | 166 |
| 179 | Serum and CSF N-acetyl aspartate levels differ in multiple sclerosis and neuromyelitis optica. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 1355-1359. | 1.9 | 29 |
| 180 | Supportive strategies to improve adherence to IFN beta-1b in Multiple Sclerosis – Results of the BetaPlus observational cohort study. <i>Journal of the Neurological Sciences</i> , 2011, 307, 120-126. | 0.6 | 59 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 181 | Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. <i>Lancet Neurology</i> , The, 2011, 10, 520-529. | 10.2 | 204 |
| 182 | Three years of experience: the Italian registry and safety data update. <i>Neurological Sciences</i> , 2011, 31, 295-297. | 1.9 | 28 |
| 183 | Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group of the Italian Neurological Society. <i>Neurological Sciences</i> , 2011, 32, 351-358. | 1.9 | 17 |
| 184 | Multiple sclerosis in Italy: cost-of-illness study. <i>Neurological Sciences</i> , 2011, 32, 787-794. | 1.9 | 33 |
| 185 | The direct cost of patients with multiple sclerosis: a survey from Italian MS centres. <i>Neurological Sciences</i> , 2011, 32, 1035-1041. | 1.9 | 22 |
| 186 | Cognitive impairment and event-related potentials in paediatric multiple sclerosis: 2-year study. <i>Neurological Sciences</i> , 2011, 32, 1043-1046. | 1.9 | 13 |
| 187 | Recommendations for the management of urinary disorders in multiple sclerosis: a consensus of the Italian Multiple Sclerosis Study Group. <i>Neurological Sciences</i> , 2011, 32, 1223-1231. | 1.9 | 43 |
| 188 | Changes in magnetic resonance imaging disease measures over 3 years in mildly disabled patients with relapsing-remitting multiple sclerosis receiving interferon β -1a in the COGNITIVE IMPAIRMENT IN MULTIPLE SCLEROSIS (COGIMUS) study. <i>BMC Neurology</i> , 2011, 11, 125. | 1.8 | 11 |
| 189 | Neopterin production and tryptophan degradation during 24-months therapy with interferon beta-1a in multiple sclerosis patients. <i>Journal of Translational Medicine</i> , 2011, 9, 42. | 4.4 | 10 |
| 190 | Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. <i>Neurology</i> , 2011, 77, 1887-1895. | 1.1 | 68 |
| 191 | Is there a future for donepezil therapy in the treatment of multiple sclerosis-related cognitive impairment?. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 1243-1246. | 2.8 | 4 |
| 192 | Cortical lesions in radiologically isolated syndrome. <i>Neurology</i> , 2011, 77, 1896-1899. | 1.1 | 73 |
| 193 | Quality of life, depression and fatigue in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: 3-year results from the COGIMUS (COGNITIVE IMPAIRMENT IN MULTIPLE SCLEROSIS) study. <i>PLoS ONE</i> , 2011, 6, e19452. | 2.5 | 74 |
| 194 | Breastfeeding is not related to postpartum relapses in multiple sclerosis. <i>Neurology</i> , 2011, 77, 145-150. | 1.1 | 135 |
| 195 | Improving the Characterization of Radiologically Isolated Syndrome Suggestive of Multiple Sclerosis. <i>PLoS ONE</i> , 2011, 6, e19452. | 2.5 | 74 |
| 196 | Psychosocial issue in children and adolescents with multiple sclerosis. <i>Neurological Sciences</i> , 2010, 31, 467-470. | 1.9 | 42 |
| 197 | Coping strategies, cognitive impairment, psychological variables and their relationship with quality of life in multiple sclerosis. <i>Neurological Sciences</i> , 2010, 31, 227-230. | 1.9 | 87 |
| 198 | Cognitive impairment in early stages of multiple sclerosis. <i>Neurological Sciences</i> , 2010, 31, 211-214. | 1.9 | 153 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 199 | Cognitive rehabilitation in children and adolescents with multiple sclerosis. <i>Neurological Sciences</i> , 2010, 31, 275-278. | 1.9 | 13 |
| 200 | Cognitive impairment in pediatric multiple sclerosis. <i>Neurological Sciences</i> , 2010, 31, 215-218. | 1.9 | 21 |
| 201 | Immunoproteasome LMP2 60HH Variant Alters MBP Epitope Generation and Reduces the Risk to Develop Multiple Sclerosis in Italian Female Population. <i>PLoS ONE</i> , 2010, 5, e9287. | 2.5 | 56 |
| 202 | Cognitive and Psychiatric Disorders in Multiple Sclerosis. <i>Blue Books of Neurology</i> , 2010, , 147-158. | 0.1 | 0 |
| 203 | Cognitive impairment predicts conversion to multiple sclerosis in clinically isolated syndromes. <i>Multiple Sclerosis Journal</i> , 2010, 16, 62-67. | 3.0 | 144 |
| 204 | Cognitive and psychosocial features in childhood and juvenile MS. <i>Neurology</i> , 2010, 75, 1134-1140. | 1.1 | 198 |
| 205 | Cortical functional reorganization and its relationship with brain structural damage in patients with benign multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2010, 16, 1326-1334. | 3.0 | 30 |
| 206 | Relevance of cognitive deterioration in early relapsing-remitting MS: a 3-year follow-up study. <i>Multiple Sclerosis Journal</i> , 2010, 16, 1474-1482. | 3.0 | 157 |
| 207 | Reliability, practice effects, and change indices for Rao's brief repeatable battery. <i>Multiple Sclerosis Journal</i> , 2010, 16, 611-617. | 3.0 | 52 |
| 208 | Pregnancy and fetal outcomes after interferon- β exposure in multiple sclerosis. <i>Neurology</i> , 2010, 75, 1794-1802. | 1.1 | 142 |
| 209 | Evolving expectations around early management of multiple sclerosis. <i>Therapeutic Advances in Neurological Disorders</i> , 2010, 3, 351-367. | 3.5 | 81 |
| 210 | Meeting Review: The management of multiple sclerosis in children: a European view. <i>Multiple Sclerosis Journal</i> , 2010, 16, 1258-1267. | 3.0 | 91 |
| 211 | Impact of cognitive impairment on coping strategies in multiple sclerosis. <i>Clinical Neurology and Neurosurgery</i> , 2010, 112, 127-130. | 1.4 | 47 |
| 212 | Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2010, 16, 68-77. | 3.0 | 89 |
| 213 | The brief neuropsychological battery for children: a screening tool for cognitive impairment in childhood and juvenile multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2009, 15, 620-626. | 3.0 | 56 |
| 214 | Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study. <i>Multiple Sclerosis Journal</i> , 2009, 15, 779-788. | 3.0 | 172 |
| 215 | Switching to Second-Line Therapies in Interferon-Beta-Treated Relapsing-Remitting Multiple Sclerosis Patients. <i>European Neurology</i> , 2009, 61, 177-182. | 1.4 | 12 |
| 216 | Subcutaneous interferon beta-1a has a positive effect on cognitive performance in mildly disabled patients with relapsing-remitting multiple sclerosis: 2-year results from the COGIMUS study. <i>Therapeutic Advances in Neurological Disorders</i> , 2009, 2, 67-77. | 3.5 | 11 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 217 | Neuropsychological and MRI measures predict short-term evolution in benign multiple sclerosis. <i>Neurology</i> , 2009, 73, 498-503. | 1.1 | 90 |
| 218 | COGNITIVE AND PSYCHOSOCIAL FEATURES OF CHILDHOOD AND JUVENILE MS. <i>Neurology</i> , 2009, 72, 1189-1190. | 1.1 | 3 |
| 219 | A short version of Rao's Brief Repeatable Battery as a screening tool for cognitive impairment in multiple sclerosis. <i>Clinical Neuropsychologist</i> , 2009, 23, 268-275. | 2.3 | 37 |
| 220 | APOE- ϵ 4 is not associated with cognitive impairment in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2009, 15, 1489-1494. | 3.0 | 21 |
| 221 | The contribution of cerebrospinal fluid oligoclonal bands to the early diagnosis of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2009, 15, 472-478. | 3.0 | 31 |
| 222 | Evidence for relative cortical sparing in benign multiple sclerosis: a longitudinal magnetic resonance imaging study. <i>Multiple Sclerosis Journal</i> , 2009, 15, 403-403. | 3.0 | 2 |
| 223 | Real-life impact of early interferon- β therapy in relapsing multiple sclerosis. <i>Annals of Neurology</i> , 2009, 66, 513-520. | 5.3 | 132 |
| 224 | Coping strategies, psychological variables and their relationship with quality of life in multiple sclerosis. <i>Neurological Sciences</i> , 2009, 30, 15-20. | 1.9 | 110 |
| 225 | Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience. <i>Neurological Sciences</i> , 2009, 30, 193-199. | 1.9 | 68 |
| 226 | The pharmacovigilance program on natalizumab in Italy: 2 years of experience. <i>Neurological Sciences</i> , 2009, 30, 163-165. | 1.9 | 16 |
| 227 | Prevalence of neuromyelitis optica spectrum disorder and phenotype distribution. <i>Journal of Neurology</i> , 2009, 256, 1891-1898. | 3.6 | 112 |
| 228 | ApolipoproteinE epsilon 4 allele is not associated with disease course and severity in multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2009, 120, 439-441. | 2.1 | 11 |
| 229 | Gray matter atrophy correlates with MS disability progression measured with MSFC but not EDSS. <i>Journal of the Neurological Sciences</i> , 2009, 284, 223. | 0.6 | 4 |
| 230 | Post-marketing of disease modifying drugs in multiple sclerosis: An exploratory analysis of gender effect in interferon beta treatment. <i>Journal of the Neurological Sciences</i> , 2009, 286, 109-113. | 0.6 | 23 |
| 231 | Improving Compliance with Interferon- β Therapy in Patients with Multiple Sclerosis. <i>CNS Drugs</i> , 2009, 23, 453-462. | 5.9 | 33 |
| 232 | Natalizumab: a country-based surveillance program. <i>Neurological Sciences</i> , 2008, 29, 235-237. | 1.9 | 10 |
| 233 | Confounders in natural history of interferon- β treated relapsing multiple sclerosis. <i>Annals of Neurology</i> , 2008, 63, 126-126. | 5.3 | 4 |
| 234 | Subclinical MS™: follow-up of four cases. <i>European Journal of Neurology</i> , 2008, 15, 858-861. | 3.3 | 35 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 235 | Differences in mesenchymal stem cell cytokine profiles between MS patients and healthy donors: Implication for assessment of disease activity and treatment. <i>Journal of Neuroimmunology</i> , 2008, 199, 142-150. | 2.3 | 71 |
| 236 | Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: An open-label comparative study of efficacy and safety. <i>Journal of the Neurological Sciences</i> , 2008, 266, 25-30. | 0.6 | 23 |
| 237 | Cognitive changes in multiple sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2008, 8, 1585-1596. | 2.8 | 141 |
| 238 | Cognitive assessment and quantitative magnetic resonance metrics can help to identify benign multiple sclerosis. <i>Neurology</i> , 2008, 71, 632-638. | 1.1 | 104 |
| 239 | Long-Term Adherence to Interferon $\hat{2}$ Therapy in Relapsing-Remitting Multiple Sclerosis. <i>European Neurology</i> , 2008, 59, 131-135. | 1.4 | 86 |
| 240 | Cognitive and psychosocial features of childhood and juvenile MS. <i>Neurology</i> , 2008, 70, 1891-1897. | 1.1 | 251 |
| 241 | Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study. <i>Multiple Sclerosis Journal</i> , 2008, 14, 1225-1233. | 3.0 | 72 |
| 242 | Caregiver quality of life in multiple sclerosis: a multicentre Italian study. <i>Multiple Sclerosis Journal</i> , 2007, 13, 412-419. | 3.0 | 78 |
| 243 | LONGITUDINAL FOLLOW-UP OF "BENIGN" MULTIPLE SCLEROSIS AT 20 YEARS. <i>Neurology</i> , 2007, 69, 938-939 | 1.1 | 5 |
| 244 | Association of Neocortical Volume Changes With Cognitive Deterioration in Relapsing-Remitting Multiple Sclerosis. <i>Archives of Neurology</i> , 2007, 64, 1157. | 4.5 | 203 |
| 245 | Autologous hematopoietic stem cell transplantation for very active relapsing-remitting multiple sclerosis: report of two cases. <i>Multiple Sclerosis Journal</i> , 2007, 13, 676-678. | 3.0 | 24 |
| 246 | Clinical outcome measures in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2007, 259, 118-122. | 0.6 | 45 |
| 247 | New natural history of interferon- $\hat{2}$ -treated relapsing multiple sclerosis. <i>Annals of Neurology</i> , 2007, 61, 300-306. | 5.3 | 251 |
| 248 | Motor evoked potentials in multiple sclerosis patients without walking limitation: amplitude vs. conduction time abnormalities. <i>Journal of Neurology</i> , 2007, 254, 220-227. | 3.6 | 33 |
| 249 | Treatment of early-onset multiple sclerosis with intramuscular interferon- $\hat{2}$ -1a: long-term results. <i>Neurological Sciences</i> , 2007, 28, 127-132. | 1.9 | 57 |
| 250 | The Rao's Brief Repeatable Battery and Stroop test: normative values with age, education and gender corrections in an Italian population. <i>Multiple Sclerosis Journal</i> , 2006, 12, 787-793. | 3.0 | 343 |
| 251 | Response to interferon-beta therapy in relapsing-remitting multiple sclerosis: a comparison of different clinical criteria. <i>Multiple Sclerosis Journal</i> , 2006, 12, 281-286. | 3.0 | 30 |
| 252 | Are there protective treatments for cognitive decline in MS?. <i>Journal of the Neurological Sciences</i> , 2006, 245, 183-186. | 0.6 | 51 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 253 | Neocortical volume decrease in relapsing-remitting multiple sclerosis with mild cognitive impairment. <i>Journal of the Neurological Sciences</i> , 2006, 245, 195-199. | 0.6 | 30 |
| 254 | Multiple sclerosis-related cognitive changes: A review of cross-sectional and longitudinal studies. <i>Journal of the Neurological Sciences</i> , 2006, 245, 41-46. | 0.6 | 465 |
| 255 | Absence of cerebrospinal fluid oligoclonal bands is associated with delayed disability progression in relapsing-remitting MS patients treated with interferon- β . <i>Journal of the Neurological Sciences</i> , 2006, 244, 97-102. | 0.6 | 40 |
| 256 | Benign multiple sclerosis. <i>Journal of Neurology</i> , 2006, 253, 1054-1059. | 3.6 | 147 |
| 257 | Brain damage as detected by magnetization transfer imaging is less pronounced in benign than in early relapsing multiple sclerosis. <i>Brain</i> , 2006, 129, 2008-2016. | 7.6 | 75 |
| 258 | The Italian Multiple Sclerosis Database Network (MSDN): the risk of worsening according to IFN β exposure in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2006, 12, 578-585. | 3.0 | 27 |
| 259 | Early prediction of the long term evolution of multiple sclerosis: the Bayesian Risk Estimate for Multiple Sclerosis (BREMS) score. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 78, 757-759. | 1.9 | 55 |
| 260 | Donepezil for memory impairment in multiple sclerosis. <i>Lancet Neurology</i> , The, 2005, 4, 72-73. | 10.2 | 13 |
| 261 | Clinical correlations of CSF single IgG bands. <i>Journal of Neurology</i> , 2005, 252, 1274-1275. | 3.6 | 11 |
| 262 | Immunomodulatory treatment of early onset multiple sclerosis: results of an Italian Co-operative Study. <i>Neurological Sciences</i> , 2005, 26, s183-s186. | 1.9 | 56 |
| 263 | Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study. <i>Multiple Sclerosis Journal</i> , 2005, 11, 420-424. | 3.0 | 99 |
| 264 | Neocortical volume decrease in relapsing-remitting MS patients with mild cognitive impairment. <i>Neurology</i> , 2004, 63, 89-93. | 1.1 | 293 |
| 265 | Pharmacoeconomic considerations of multiple sclerosis therapy with the new disease-modifying agents. <i>Expert Opinion on Pharmacotherapy</i> , 2004, 5, 2115-2126. | 1.8 | 12 |
| 266 | The prevalence of pain in multiple sclerosis. <i>Neurology</i> , 2004, 63, 919-921. | 1.1 | 274 |
| 267 | Altered cerebellar functional connectivity mediates potential adaptive plasticity in patients with multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2004, 75, 840-846. | 1.9 | 74 |
| 268 | European validation of a standardized clinical description of multiple sclerosis. <i>Journal of Neurology</i> , 2004, 251, 1472-1480. | 3.6 | 40 |
| 269 | Cerebrospinal fluid findings in Devic's neuromyelitis optica. <i>Neurological Sciences</i> , 2004, 25, s368-s370. | 1.9 | 37 |
| 270 | Italian studies on early-onset multiple sclerosis: the present and the future. <i>Neurological Sciences</i> , 2004, 25, s346-s349. | 1.9 | 20 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 271 | A double blind, placebo-controlled, phase II, add-on study of cyclophosphamide (CTX) for 24 months in patients affected by multiple sclerosis on a background therapy with interferon-beta study denomination: CYCLIN. <i>Journal of the Neurological Sciences</i> , 2004, 223, 69-71. | 0.6 | 27 |
| 272 | Influence of Apolipoprotein E ϵ 4 Genotype on Brain Tissue Integrity in Relapsing-Remitting Multiple Sclerosis. <i>Archives of Neurology</i> , 2004, 61, 536. | 4.5 | 45 |
| 273 | Interobserver agreement on Poser's and the new McDonald's diagnostic criteria for multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2003, 9, 481-485. | 3.0 | 16 |
| 274 | Safety and tolerability of cyclophosphamide "pulses" in multiple sclerosis: a prospective study in a clinical cohort. <i>Multiple Sclerosis Journal</i> , 2003, 9, 446-450. | 3.0 | 37 |
| 275 | Can the Expanded Disability Status Scale be assessed by telephone?. <i>Multiple Sclerosis Journal</i> , 2003, 9, 154-159. | 3.0 | 123 |
| 276 | Changes in Neuropsychological Test Performance Over the Workday in Multiple Sclerosis. <i>Clinical Neuropsychologist</i> , 2003, 17, 551-560. | 2.3 | 38 |
| 277 | Cognitive dysfunction in multiple sclerosis: current approaches to clinical management. <i>Expert Review of Neurotherapeutics</i> , 2002, 2, 731-742. | 2.8 | 1 |
| 278 | The costs of multiple sclerosis: a cross-sectional, multicenter cost-of-illness study in Italy. <i>Journal of Neurology</i> , 2002, 249, 152-163. | 3.6 | 81 |
| 279 | Cognitive Dysfunction in Early-Onset Multiple Sclerosis. <i>Archives of Neurology</i> , 2001, 58, 1602. | 4.5 | 586 |
| 280 | A prospective study on the natural history of multiple sclerosis: clues to the conduct and interpretation of clinical trials. <i>Journal of the Neurological Sciences</i> , 1999, 168, 96-106. | 0.6 | 112 |
| 281 | Quantification of impairment in MS: discussion of the scales in use. <i>Multiple Sclerosis Journal</i> , 1999, 5, 216-219. | 3.0 | 54 |
| 282 | Cognitive Impairment in Early-Onset Multiple Sclerosis. <i>Archives of Neurology</i> , 1995, 52, 168. | 4.5 | 329 |
| 283 | The influence of high dose intravenous immunoglobulins on immunological and metabolic pattern in newly diagnosed type I diabetic patients. <i>Journal of Autoimmunity</i> , 1990, 3, 587-592. | 6.5 | 16 |
| 284 | Cognitive dysfunction in pediatric-onset multiple sclerosis. , 0, , 134-143. | | 2 |
| 285 | Do patients' and referral centers' characteristics influence multiple sclerosis phenotypes? Results from the Italian multiple sclerosis and related disorders register. <i>Neurological Sciences</i> , 0, , . | 1.9 | 1 |